Medical News Observer

• Inhalable nanoparticles interact with cancer-related protease enzymes, releasing DNA barcodes in urine.
• A paper test strip using lateral flow assay identifies DNA signals, therefore offering a simple, non-invasive point-of-care diagnosis.
• It is promising for early detection, especially in regions with limited medical technology.

Overview

The Massachusetts Institute of Technology researchers have developed an innovative lung cancer diagnostic technique that uses inhalable nanoparticle sensors, detectable through a simple urine test. This method, aimed at replacing or supplementing traditional CT scans, is particularly beneficial for low- and middle-income countries with limited access to advanced medical equipment. 

Nanoparticles in Cancer Detection

The technology developed by the MIT team uses polymer nanoparticles that can be delivered through an inhaler or a nebulizer. These nanoparticles are designed to detect cancer-related proteases, which are enzymes that are often overactive in tumors. When these enzymes come into contact with the nanoparticles, they release DNA barcodes that are then excreted in the urine. This DNA signal can be easily identified using a simple paper test strip through lateral flow assay.

Animal Studies

This inhalable nanoparticle technology has shown promising results in detecting early-stage tumors in an autochthonous lung adenocarcinoma mouse model with high sensitivity and specificity. 

Next steps

The researchers are now looking to extend this approach to human trials and have highlighted the potential for significant improvements in lung cancer screening in areas with limited access to advanced medical technology. 

Future implications

This nanotechnology platform offers a more accessible, efficient, and non-invasive approach to lung cancer diagnosis, potentially transforming cancer screening practices globally.

Reference

Zhong, Qian, Edward K. W. Tan, Carmen Martin-Alonso, Tiziana Parisi, Liangliang Hao, Jesse D. Kirkpatrick, Tarek Fadel, Heather E. Fleming, Tyler Jacks, and Sangeeta N. Bhatia. 2024. “Inhalable Point-of-Care Urinary Diagnostic Platform.” Science Advances 10 (1): eadj9591. https://doi.org/10.1126/sciadv.adj9591.